Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
about
Biological response modifiers in cancerTherapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesContemporary use of bevacizumab in ovarian cancerHuman melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2Ponatinib reduces viability, migration, and functionality of human endothelial cells.Bevacizumab suppression of establishment of micrometastases in experimental ocular melanomaCytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabVascular endothelial growth factor (VEGF) -2578C/A and -460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case-control studies.Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.Angiogenesis: a curse or cure?Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.Targeting protein kinases in cancer therapy: a success?The HMG-CoA reductase pathway, statins and angioprevention.In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.Anti-angiogenic therapy: Prospects for treatment of ocular tumors.Emerging drugs to replace current leaders in first-line therapy for breast cancer.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Bevacizumab and non-small-cell lung cancer: starving the enemy to survive.Bevacizumab: overview of the literature.The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis.Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity.Angiogenesis after administration of basic fibroblast growth factor induces proliferation and differentiation of mesenchymal stem cells in elastic perichondrium in an in vivo model: mini review of three sequential republication-abridged reports
P2860
Q24685049-F6CB8AAE-757B-4BDF-9256-6EEF6470EB45Q26777679-AE11D0FF-0484-4599-B8DF-EB9EBA97F9CBQ27023510-3F2609B6-57C7-45A4-97D4-29CC0E4E0669Q30438929-C5C92E85-BE25-4E3C-844F-95FA1396EC44Q33364077-8BD4E579-F82B-4A4C-B55B-76CC8615048BQ33867266-E5F3498B-5E26-4652-B13C-89C5FADD72CAQ33995228-A002EC63-8877-4FEB-B492-F77C82D36690Q34620205-862A86C4-FD06-4151-B943-8D924693E8AAQ34693856-E73B4018-A85E-4A09-973F-1E2F682E7489Q34694813-8DAC6BAE-89B8-468E-B36B-E88AE6FA5A72Q34975344-6497DAB9-385C-463A-82A5-2FE367336705Q35021664-2D4FEBCC-89C0-4733-B741-EB7EAC1B3F00Q35088365-F5BDDAB7-E80A-4FBB-9E56-8CDEA6C22BB7Q35521647-5442B216-C521-4BE6-BA01-B52BBA75E586Q35766780-A9832721-C58B-4BD1-94BE-2E11898940AFQ35987779-FE616A4D-55F3-4B50-9822-33EEF93294C6Q36414196-6FCBCC3E-0EF9-4222-9A9B-3221E2FD2239Q36438808-A139D536-AF83-4FF4-B0DC-3A9AC6E5396FQ36494268-CA9DB74C-6E7D-468C-B0AF-A3661165237CQ36567094-79EF17D9-7017-478F-80BE-2E80030199BBQ36580598-B4113686-A8FF-422D-9879-E80361A16A9DQ36787777-7F0D5BB7-C8F2-4065-A01F-CE84BC3B5514Q36897416-2E186285-1838-443B-B510-06246F000B1EQ38010797-94422A5E-C6D0-4FC8-BCDE-58CDB743CBCBQ39500842-68C7DA40-EFEE-4539-8171-D306C8A54B56Q40411720-F49D41BD-82D2-4681-B491-D953B3463AC8Q42926957-F241B78C-3C58-45F7-844D-1BB0B84B7778Q49996824-59D8A927-A6DB-4AF8-A0BE-4A05C3BE3BC3Q50886676-FF6A5E75-6AAA-451C-B37E-73F9D6C69BF9Q52935906-FC6B941A-EF43-409C-BC1E-FB9D25809D1DQ57482804-85CC35B8-15B2-46B9-AE91-84736C2C5792
P2860
Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@ast
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@en
type
label
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@ast
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@en
prefLabel
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@ast
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@en
P2860
P356
P1476
Bevacizumab: an angiogenesis i ...... rectal and other malignancies.
@en
P2093
Patrick J Medina
Stacey D Zondor
P2860
P304
P356
10.1345/APH.1D470
P407
P577
2004-06-08T00:00:00Z